Antipsychotic therapy during early and late pregnancy. A systematic review.

Department of Mental Health ASL Salerno 1, Mental Health Center n. 4, Piazza Galdi, 841013 Cava de' Tirreni (Salerno), Italy.
Schizophrenia Bulletin (Impact Factor: 8.61). 10/2008; 36(3):518-44. DOI: 10.1093/schbul/sbn107
Source: PubMed

ABSTRACT Both first- (FGAs) and second-generation antipsychotics (SGAs) are routinely used in treating severe and persistent psychiatric disorders. However, until now no articles have analyzed systematically the safety of both classes of psychotropics during pregnancy. DATA SOURCES AND SEARCH STRATEGY: Medical literature information published in any language since 1950 was identified using MEDLINE/PubMed, TOXNET, EMBASE, and The Cochrane Library. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from companies developing drugs. Search terms were pregnancy, psychotropic drugs, (a)typical-first-second-generation antipsychotics, and neuroleptics. A separate search was also conducted to complete the safety profile of each reviewed medication. Searches were last updated on July 2008.
All articles reporting primary data on the outcome of pregnancies exposed to antipsychotics were acquired, without methodological limitations.
Reviewed information was too limited to draw definite conclusions on structural teratogenicity of FGAs and SGAs. Both classes of drugs seem to be associated with an increased risk of neonatal complications. However, most SGAs appear to increase risk of gestational metabolic complications and babies large for gestational age and with mean birth weight significantly heavier as compared with those exposed to FGAs. These risks have been reported rarely with FGAs. Hence, the choice of the less harmful option in pregnancy should be limited to FGAs in drug-naive patients. When pregnancy occurs during antipsychotic treatment, the choice to continue the previous therapy should be preferred.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treating pregnant women with bipolar disorder is among the most challenging clinical endeavors. Patients and clinicians are faced with difficult choices at every turn, and no approach is without risk. Stopping effective pharmacotherapy during pregnancy exposes the patient and her baby to potential harms related to bipolar relapses and residual mood symptom-related dysfunction. Continuing effective pharmacotherapy during pregnancy may prevent these occurrences for many; however, some of the most effective pharmacotherapies (such as valproate) have been associated with the occurrence of congenital malformations or other adverse neonatal effects in offspring. Very little is known about the reproductive safety profile and clinical effectiveness of atypical antipsychotic drugs when used to treat bipolar disorder during pregnancy. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated or undertreated maternal bipolar disorder during pregnancy, the effectiveness of interventions for bipolar disorder management during pregnancy, and potential obstetric, fetal, and neonatal risks associated with core foundational pharmacotherapies for bipolar disorder.
    Drug, Healthcare and Patient Safety 01/2015; 7:7-29. DOI:10.2147/DHPS.S50556
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder is a disease that typically begins in adolescence and early adulthood, namely during the reproductive period. The treatment of female cases during their reproductive years is very important because of the teratogenic effects of psychotropic drugs. It has been stated that the use of classical antipsychotics during pregnancy was not associated with congenital malformations or low birth weight. While all drugs pass through the placenta, quetiapine shows the lowest degree of placenta transit of all the antipsychotics. Studies with animals have not showed any teratogenic effect. Even though studies with humans are very limited with respect to embryonic/ fetal risk assessment, recent studies have shown no increased risk of birth defects in quetiapine exposed babies and when compared to other treatment alternatives, quetiapine can be used safely in pregnancy. In this article, we report that no negative data has been found in terms of teratogenicity or perinatal complications in the cases of four pregnant women being treated with quetiapine in the manic and depressive episodes of bipolar disorder and it is also reported that quetiapine can reliably be used during pregnancy.
    Bulletin of Clinical Psychopharmacology 12/2014; DOI:10.5455/bcp.20140714030311 · 0.37 Impact Factor
  • Journal of Obstetrics and Gynaecology 02/2015; DOI:10.3109/01443615.2014.991292 · 0.60 Impact Factor

Full-text (2 Sources)

Available from
May 17, 2014